NCT02871427 is a Phase 2 clinical trial of Nelotanserin in Lewy Body Dementia, sponsored by Axovant Sciences Ltd..

Who is sponsoring NCT02871427?

NCT02871427 is sponsored by Axovant Sciences Ltd..

What drugs are being tested in NCT02871427?

Interventions in NCT02871427: Nelotanserin.

What condition does NCT02871427 study?

NCT02871427 studies Lewy Body Dementia, Dementia With Lewy Bodies, Parkinson's Disease Dementia, Visual Hallucinations, REM Sleep Behavior Disorder.

Is NCT02871427 still recruiting?

NCT02871427 is currently terminated. Last updated 27 March 2019.

Last reviewed 2019-03-27 · How we verify

NCT02871427

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Terminated Phase 2 Last updated 27 March 2019

What this trial tests

Phase 2 trial testing Nelotanserin in Lewy Body Dementia in 80 participants. Terminated before completion.

Timeline

20 October 2016

Primary endpoint
17 January 2019

17 January 2019

Quick facts

Lead sponsor	Axovant Sciences Ltd.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	20 October 2016
Primary completion	17 January 2019
Estimated completion	17 January 2019
Sites	19 locations across United States

Drugs / interventions tested

Nelotanserin — full drug profile →

Conditions studied

Lewy Body Dementia — all drugs for Lewy Body Dementia →
Dementia With Lewy Bodies — all drugs for Dementia With Lewy Bodies →
Parkinson's Disease Dementia — all drugs for Parkinson's Disease Dementia →
Visual Hallucinations — all drugs for Visual Hallucinations →

Sponsor

Axovant Sciences Ltd. — full company profile →

Who can join

50 and older, any sex, with Lewy Body Dementia or Dementia With Lewy Bodies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer's disease.
Morrone CD, Raghuraman R, Hussaini SA, Yu WH. · · 2023 · cited 40× · PMID 37085942 · DOI 10.1186/s13024-023-00617-4
A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials.
Gilat M, Marshall NS, Testelmans D, Buyse B, et al · · 2022 · cited 36× · PMID 33410930 · DOI 10.1007/s00415-020-10353-0
Advances in dementia with Lewy bodies.
Armstrong MJ. · · 2021 · cited 20× · PMID 34840608 · DOI 10.1177/17562864211057666
Drug Discovery and Development Targeting Dementia.
Zagórska A, Czopek A, Fryc M, Jaromin A, et al · · 2023 · cited 18× · PMID 37259302 · DOI 10.3390/ph16020151
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.
Green H, Tsitsi P, Markaki I, Aarsland D, et al · · 2019 · cited 17× · PMID 30687888 · DOI 10.1007/s40263-018-0601-x
Lewy Body Dementias: Controversies and Drug Development.
Chiu SY, Bowers D, Armstrong MJ. · · 2022 · cited 5× · PMID 34859379 · DOI 10.1007/s13311-021-01161-z

Verify or expand the search:

Other recruiting trials for Lewy Body Dementia

Currently open trials in the same condition.

NCT06862557 — Pulsed Electromagnetic Field Treatment With Dementia Patients · NA · recruiting
NCT06631742 — Exergaming Revolution in Dementia · NA · recruiting
NCT06389032 — PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia · NA · active not recruiting
NCT06337578 — Advances in Telephone-based Cognitive Screening Procedures · recruiting
NCT06005935 — Environmental and Reproductive Health Risk for Lewy Body Dementia · active not recruiting

Other Axovant Sciences Ltd. trials

Trials by the same sponsor.

NCT02586909 — 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02871427 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Axovant Sciences Ltd.
Last refreshed: 27 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02871427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing